OBJECTIVE: To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.
DESIGN: We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.
SETTING: Family Medicine Residency, Mike O'Callaghan Military Medical Center.
MAIN OUTCOME MEASURES: Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.
RESULTS: Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.
CONCLUSION: MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.
- Blood/drug effects
- Blood Pressure/drug effects
- Dimethyl Sulfoxide/therapeutic use
- Double-Blind Method
- Kidney/drug effects
- Liver/drug effects
- Low Back Pain/drug therapy
- Middle Aged
- Osteoarthritis/drug therapy
- Sulfones/therapeutic use